Iovance Biotherapeutics Raises 2026 Revenue Guidance

07:21 AM EDT, 09/29/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) said Tuesday it raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from prior outlook of $350 million to $370 million. Analysts polled by FactSet expect $402.8 million. Iovance said the outlook raise is driven by strong US demand for Amtagvi and Proleukin. Shares of the company were up more than 5% pre-bell Tuesday.